Protocol Ledger

NCT05481151 · Phase III · ACTIVE NOT RECRUITING

A Study to Assess Efficacy, Safety, and Tolerability of P1101 in Adult Patients With PV

Interventional Phase III clinical trial protocol NCT05481151 sponsored by PharmaEssentia in Rare Genetic, Women's Health, and Other, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2022-10-26 Enrollment: 111 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT05481151
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)111 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)3 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05481151
Protocol FieldVerified Registry Value
NCT IdentifierNCT05481151
Consolidated Lead SponsorPharmaEssentia
Therapeutic Condition CohortRare Genetic, Women's Health, and Other
Clinical Trial PhasePhase III
Overall Recruitment StatusACTIVE NOT RECRUITING
Registered Enrollment111 participants (ACTUAL)
Registered Start Date2022-10-26
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT05481151
Hospital Research SiteLocationSite Profile
Washington University and Siteman Cancer CenterSaint Louis, MOOpen Hospital Dossier ->
Mount Sinai Hospital and Icahn School of MedicineNew York, NYOpen Hospital Dossier ->
Montefiore Medical CenterThe Bronx, NYOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Rare Genetic, Women's Health, and Other Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI